Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-733-4 | CAS number: 12028-48-7
Carcinogenicity
Administrative data
Description of key information
Based on the available data of sodium tungstate for read-across, ammonium metatungstate is not classified as a mutagen and there is no evidence from repeat dose oral studies on sodium tungstate to indicate that it would induce hyperplasia and/or pre-neoplastic lesions.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
No data of sufficient quality data on the carcinogenicity of ammonium metatungstate are available. Classification is not possible due to data lacking.
Additional information
No data of sufficient quality on the carcinogencity of ammonium metatungstate (target substance) are available. However, toxicity data are available for sodium tungstate (source substance).
Due to similar or lower transformation/dissolution results for ammonium metatungstate (target substance) than sodium tungstate (source substance), the resulting toxicity potential is expected to be similar or lower, so read-across is appropriate. In addition, read-across is justified because the classification and labelling is the same or less severe for the target substance and the PBT/vPvB profile is the same. Finally, the dose descriptors are, or are expected to be, sufficiently similar or higher for the target substance, and read-across to the source substance is adequately protective. For more details, refer to the read-across category approach description in the Category section of this IUCLID submission or Annex 3 of the CSR.
According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. Based on the available data from read across to sodium tungstate, hexaaamonium metatungstate is not classified as a mutagen and there is no evidence from repeat dose oral studies on sodium tungstate to indicate that it would induce hyperplasia and/or pre-neoplastic lesions.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
